Management issues for elderly patients with breast cancer

被引:27
作者
Extermann M. [1 ]
机构
[1] Moffitt Cancer Center, Tampa, FL 33612
关键词
Breast Cancer; Tamoxifen; Docetaxel; Trastuzumab; Clin Oncol;
D O I
10.1007/s11864-004-0048-9
中图分类号
学科分类号
摘要
Fifty percent of breast cancers occur after the age of 65 years and 25% occur after the age of 75 years. Encountering a breast cancer in an older woman is frequent. After years of death of data specific to the elderly, some evidence is beginning to accumulate concerning breast cancer in the older woman. Recent data from mammography studies confirm its effectives in women with 10 years or more of life expectancy (perhaps even 5 years). Epidemiologic and randomized studies demonstrate that a proper surgery and adjuvant treatment can decrease relapse and improve survival in patients older than 80 years. Radiation therapy studies show a decrease in local relapse even in patients older than 70 years. Adjuvant hormonal therapy has essentially the same effectiveness as in younger women. Chemotherapy has a role in patients older than 70 years. Consensus statements, such as the St. Gallen consensus, have dropped the age limit of 70 years from their recommendations. Comorbidity and life expectancy should be taken into account for proper selection of adjuvant treatment. The treatment of metastatic breast cancer has evolved significantly with the introduction of aromatase inhibitors, new chemotherapeutic agents, and targeted biologic agents. New chemotherapeutic agents are as effective as single agents compared to older and more toxic drug combinations. The cumulative result of the introduction of these new agents, at a population level, is a 7.5-month increase in the median survival time of patients with metastatic breast cancer over the past decade. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:161 / 169
页数:8
相关论文
共 61 条
[21]  
Wyckoff J., Greenberg H., Sanderson R., Et al., Breast irradiation in the older woman: A toxicity study, J. Am. Geriatr. Soc., 42, pp. 150-152, (1994)
[22]  
Buzdar A., The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer: Updated efficacy results based on a median follow-up of 47 months, San Antonio Breast Cancer Symp., (2002)
[23]  
Fisher B., Dignam J., Bryant J., Wolmark N., Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial, J. Natl. Cancer Inst., 93, pp. 684-690, (2001)
[24]  
Stewart H.J., Prescott R.J., Forrest A.P., Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years, J. Natl. Cancer Inst., 93, pp. 456-462, (2001)
[25]  
Tormey D.C., Gray R., Falkson H.C., Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group, J. Natl. Cancer Inst., 88, pp. 1828-1833, (1996)
[26]  
Goss P.E., Ingle I.N., Martino S., Et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med., 349, pp. 1793-1802, (2003)
[27]  
Boccardo F., Rubagotti A., Amoroso D., Et al., Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study, J. Clin. Oncol., 19, pp. 4209-4215, (2001)
[28]  
Love R.R., Barden H.S., Mazess R.B., Et al., Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years, Arch. Intern. Med., 154, pp. 2585-2588, (1994)
[29]  
Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, 352, pp. 930-942, (1998)
[30]  
National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer November 1-3, 2000, J. Natl. Cancer Inst. Monogr., 30, pp. 5-15, (2001)